Department of Urology, Eberhard-Karls University, Tübingen, Germany.
BJU Int. 2010 Feb;105(4):468-71. doi: 10.1111/j.1464-410X.2009.08739.x. Epub 2009 Jul 7.
To analyse retrospectively the clinicopathological features of incidental prostate cancer in patients undergoing radical cystoprostatovesiculectomy (RCP) for invasive bladder cancer, as recent studies suggest that prostatic apex-sparing surgery in patients undergoing RCP improves urinary continence and erectile function after surgery, but in those with incidental prostate cancer, leaving the apical region endangers the oncological outcome.
From 2004 to 2007, at our institution, 95 men had RCP for invasive bladder cancer. We reviewed their clinicopathological variables, especially apical involvement, and the course of prostate-specific antigen (PSA) levels before and after surgery. We compared clinically significant and insignificant prostate cancers.
Of the 95 patients, 26 had incidental prostate cancer (mean age 68 years, range 53-80) on definitive histological examination. The mean (sd, range) preoperative PSA level in all 26 men was 3.6 (0.8, 0.2-14) ng/mL, but six of the 26 patients had preoperative PSA levels of >4 ng/mL and one other had suspicious findings on a digital rectal examination. Involvement of the apex was histologically confirmed in seven of the 26 patients (27%), including four with significant prostate cancer (P = 0.039). Preoperative PSA levels did not differ significantly between the seven patients with significant and 19 with insignificant prostate cancer, but seven patients with apical involvement had significantly higher PSA levels before RCP than the 19 who did not (P < 0.04). PSA levels after RCP remained below the limit of detection in all patients over a mean (range) follow-up 14.3 (3-32) months.
In our series, preserving the apex of the prostate to decrease morbidity after RCP carried a 7.3% risk (seven of 95 patients) of leaving significant cancer in the residual prostatic tissue. No preoperative clinical value could exclude apical involvement. Therefore, our findings stress the oncological need for a careful and complete excision of the prostate during RCP.
回顾性分析因浸润性膀胱癌行根治性膀胱前列腺切除术(RCP)的患者中偶然发现的前列腺癌的临床病理特征,因为最近的研究表明,在接受 RCP 的患者中进行前列腺尖部保留手术可以改善手术后的尿控和勃起功能,但在患有偶然发现的前列腺癌的患者中,留下尖部会危及肿瘤学结果。
2004 年至 2007 年,在我们机构,95 名男性因浸润性膀胱癌行 RCP。我们回顾了他们的临床病理变量,特别是尖部受累情况,以及手术前后前列腺特异性抗原(PSA)水平的变化。我们比较了有临床意义和无临床意义的前列腺癌。
在 95 例患者中,26 例在明确的组织学检查中偶然发现前列腺癌(平均年龄 68 岁,范围 53-80)。26 名男性的平均(标准差,范围)术前 PSA 水平为 3.6(0.8,0.2-14)ng/ml,但其中 6 名患者术前 PSA 水平>4ng/ml,另 1 名患者直肠指检有可疑发现。26 例患者中有 7 例(27%)在组织学上证实了尖部受累,其中 4 例为有临床意义的前列腺癌(P=0.039)。有临床意义的前列腺癌的 7 名患者和无临床意义的前列腺癌的 19 名患者之间的术前 PSA 水平没有显著差异,但有尖部受累的 7 名患者在接受 RCP 前的 PSA 水平明显高于 19 名无尖部受累的患者(P<0.04)。在平均(范围)14.3(3-32)个月的随访中,所有患者的 PSA 水平在 RCP 后均低于检测限。
在我们的系列研究中,为了降低 RCP 后的发病率而保留前列腺的尖部,有 7.3%(95 例患者中的 7 例)的风险会留下有临床意义的肿瘤在残留的前列腺组织中。没有术前的临床价值可以排除尖部受累。因此,我们的研究结果强调了在 RCP 中仔细和完整切除前列腺的肿瘤学必要性。